Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Abbott (ABT) Gains in Core Diagnostics With FDA Nod for Alinity H
by Zacks Equity Research
Abbott's (ABT) Alinity h-series not only delivers technological innovation but also addresses the realistic challenges faced by modern healthcare systems.
Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport
by Zacks Equity Research
Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on its strategic expansion in the global market and recovery within the Nutrition segment.
Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line
by Zacks Equity Research
Asensus Surgical (ASXC) reports a significant increase in total surgical procedures completed utilizing the Senhance System.
National Vision (EYE) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) second-quarter 2023 performance highlights positive comparable store sales growth, retention and recruitment trends.
The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Abbott Laboratories, HCA Healthcare and General Motors
by Zacks Equity Research
JPMorgan Chase, Salesforce, Abbott Laboratories, HCA Healthcare and General Motors are included in this Analyst Blog.
Top Stock Reports for JPMorgan Chase, Salesforce & Abbott Laboratories
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Abbott Laboratories (ABT).
Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed
by Zacks Equity Research
Charles River (CRL) registers robust growth in small research models, research model services and the Safety Assessment business.
Insulet (PODD) Q2 Earnings Beat, Sales Growth View Raised
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 gains market share in the second quarter within the diabetes technology market as the only FDA-approved fully disposable, pod-based automated insulin delivery system.
QIAGEN (QGEN) Q2 Earnings and Revenues Top, '23 View Slashed
by Zacks Equity Research
QIAGEN (QGEN) surpasses the earnings and revenue outlook in the second quarter of 2023 amid a challenging macro environment.
SmileDirectClub (SDC) Q2 Earnings Miss Estimates, '23 View Up
by Zacks Equity Research
SmileDirectClub (SDC) reports a higher-than-expected loss in the second quarter of 2023.
Henry Schein (HSIC) Q2 Earnings Top, Operating Margin Dips
by Zacks Equity Research
Henry Schein's (HSIC) second quarter 2023 performance demonstrates strength in the North American dental business.
Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.
ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.
Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View
by Zacks Equity Research
Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.
Stryker (SYK) Q2 Earnings Beat Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.
Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Cigna (CI) Q2 Earnings Beat on Strong U.S. Commercial Unit
by Zacks Equity Research
Cigna's (CI) Q2 results reflect solid premium rate hikes and a growing membership base across its U.S. Commercial and Medicare Advantage businesses.
PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.
Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.
BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.
Envista (NVST) Q2 Earnings Top Estimates, Margins Expands
by Zacks Equity Research
Consistent growth in the Specialty Products & Technologies segment and a return to growth in the Equipment & Consumables segment drive Envista's (NVST) Q2 revenues.
Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
STERIS (STE) Q1 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Barring Life Sciences and Dental, rest of STERIS (STE) operating segments report organic revenue growth in fiscal Q1.
McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.